Global Heparin Market Charts a Path to 5% Growth by 2026
Rising
prevalence of chronic diseases such as venous thromboembolism, pulmonary
embolism, renal diseases, and cardiovascular disorders, the growing geriatric
population, the high demand for anticoagulants, the growing use of heparin in
various surgeries such as orthopedic and heart surgeries, and the growing
availability of synthetic and semi-synthetic heparin mimetics that aid in
cancer, coagulation, and inflammatory disease treatment are some of the key
factors driving the global heparin market.
Heparin is a
prescription injectable anticoagulant used to treat and prevent the symptoms of
blood clots caused by medical disorders or medical treatments. It's also
utilized to make an anti-clotting surface within medical devices like dialysis
machines and test tubes.
Heparin is being more widely used
in a variety of applications. What is driving the growth of the heparin
market?
Anticoagulants act by reducing the ability of the blood to clot. It aids in the prevention of clot formation as well as the prevention of additional clot enlargement. As a result, it can be employed in a variety of applications, including:
- Prevent or treat certain blood vessel, heart, and lung conditions
- Prevent blood clotting during open-heart surgery, bypass surgery, kidney dialysis, and blood transfusions
- Prevention of deep vein thrombosis
- Prevention of a blood clot following percutaneous coronary intervention
The use of low molecular weight
unfractionated heparin instead of heparin to prevent deep vein thrombosis or
pulmonary embolism is increasing. Increases Demand
Low-molecular-weight heparins have significant advantages over UFH,
leading to their increased use for thromboembolic indications such as deep vein
thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). LMWH
outperforms heparin in terms of bioavailability and half-life, easier dose,
predictable anticoagulant response, lesser risk of heparin-induced
thrombocytopenia (HIT), and lower risk of osteoporosis.
The Potential Role of Heparin
in Covid-19 Patients Boosts the Worldwide Heparin Market
Many
patients with COVID-19 develop a clinically significant coagulopathy. COVID-19
infections can lead to an increased risk of blood clots. These blood clots can
lead to individuals being admitted to hospital, or, unfortunately in severe
cases, death. Also, patients with COVID-19 are at high risk for developing
clinically significant large-vessel thrombosis. Therefore, early use of
anticoagulation may reduce the risk of coagulopathy, microthrombus formation,
and organ damage.
Explored Detailed
Insights on Heparin Market with TOC and a Sample Report PDF @ https://www.globenewswire.com/en/news-release/2022/11/07/2549846/0/en/Global-Heparin-Market-is-expected-to-grow-at-a-decent-rate-of-5-by-2026-Growing-Application-of-Heparin-in-Orthopedic-and-Heart-Surgeries.html
Upcoming Market Challenges: Global Heparin
Market
The side effects associated with the use
of heparin drugs and the presence of another anticoagulant in the market are
the major factors restraining the growth of the market.
North America has the largest market
share, but APAC is expected to grow the fastest in the heparin market.
The
heparin market is dominated by North America, followed by Europe and Asia
Pacific. This is mostly due to the region's high chronic disease burden, the
presence of advanced and robust healthcare infrastructure, rising need for
heparin in various procedures, and rising occurrences of cardiovascular
ailments. However, Asia-Pacific is expected to grow significantly during the
forecast period due to the region's position as the largest supplier base of
crude heparin, the rising incidence of venous thromboembolism and
cardiovascular diseases, an increase in surgical procedures, and an increase in
the geriatric population.
Competitive
Landscape Analysis: Heparin Market
The global heparin market is marked by the presence of established market
players such as Baxter International Inc., B. Braun Holding GmbH & Co. KG,
Dr. Reddy’s Laboratories Ltd., and Fresenius SE & Co KGaA among others.
Companies are
implementing both organic and inorganic growth strategies in order to increase
their market share in the heparin market.
To increase their market share, all of the main competitors in the global heparin market are pursuing organic and inorganic growth methods such as collaborations, acquisitions, and expansions. As an example,
- In February 2022, Techdow USA Inc. announced the launch of its Heparin Sodium Injection, USP in the United States market.
- In January 2022, Ohio-based biotechnology company Optimvia Pharmaceuticals announced the development of a synthetic method for creating large quantities of heparin, which is used to make a common blood thinner at a reasonable price.
Get Detailed
Insights on Heparin Market with TOC and a Sample Report PDF @ https://meditechinsights.com/global-heparin-market/
About Medi-Tech Insights:
Medi-Tech Insights is a
healthcare-focused business research & insights firm. Our clients include
Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We
have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology,
Medical Devices & Pharma Services.
Contact:
Ruta
Halde
Associate,
Medi-Tech Insights
Comments
Post a Comment